Restoring the Patent System: Countering Supreme Court Attacks on What Can be Patented David Kappos Robert Armitage Bruce Sunstein Denise Kettelberger,

Slides:



Advertisements
Similar presentations
Second level — Third level Fourth level »Fifth level CLS Bank And Its Aftermath Presented By: Joseph A. Calvaruso Orrick, Herrington & Sutcliffe LLP ©
Advertisements

Recent Cases on Patentable Subject Matter and Patent Exhaustion Mojdeh Bahar, J.D., M.A. Chief, Cancer Branch Office of Technology Transfer National Institutes.
What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
1 Bioinformatics Practice Considerations October 20, 2011 Ling Zhong, Ph.D.
© 2011 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Patenting Methods of Medical Treatment in the United States AIPPI 2011 Forum/ExCo Peter.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
11 Post-Bilski Case Law Update Remy Yucel Director, Central Reexamination Unit.
1 Click to edit Master Changes to the U.S. Patent System Steven Steger September 4, 2014.
Patents Copyright © Jeffrey Pittman. Pittman - Cyberlaw & E- Commerce 2 Legal Framework of Patents The U.S. Constitution, Article 1, Section 8:
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
2015 AIPLA IP Practice in Europe Committee June, 2015 Phil Swain Foley Hoag LLP Boston, MA - USA The Effect of Alice v CLS Bank on patent subject matter.
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
Patentable Subject Matter and Design Patents,Trademarks, and Copyrights David L. Hecht, J.D., M.B.A, B.S.E.E.
H o w t h e F e d e r a l C o u r t s a r e O r g a n i z e d H o w d o t h e d if f e r e n t k i n d s o f c o u r ts fi t t o g e t h e r ? Congress.
Welcome to our Quiz Show. So you want to be as smart as a State Court Judge?
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
Biotechnology/Chemical/Pharmaceutical Customer Partnership: Recent Examiner Training and Developments Under 35 USC § 101 Drew Hirshfeld Deputy Commissioner.
An invention is a unique or novel device, method, composition or process. It may be an improvement upon a machine or product, or a new process for creating.
Biotechnology Assignment 7 Patent Law. Case study 1 –Federal Supreme Court Germany (Bundesgerichshof), 27 March 1969 (Red Dove), IIC, 1970, 136 –Answer.
Public Policy Considerations and Patent Eligible Subject Matter Relating to Diagnostic Inventions Disclaimer: Any views expressed here are offered in order.
Patent Eligible Subject Matter: Where Are We Now? A Presentation to CPTCLA September 23, 2011 Mike Connor Alston & Bird LLP Atlanta | Brussels | Charlotte.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
Prosecution Group Luncheon November, Prioritized Examination—37 CFR “No fault” special status under 1.102(e) Request made with filing of nonprovisional.
Post-Bilski Patent Prosecution IP Osgoode March 13, 2009 Bob Nakano McCarthy Tétrault LLP.
Class Seven: Intellectual Property Patents, Trademarks and Copyrights.
The Inferior Courts Judicial Branch Inferior Courts Lower federal courts created by congress in the Judiciary Act of 1789 –Currently 94 of them –89 federal.
1 1 AIPLA Firm Logo American Intellectual Property Law Association The Presumption of Patent Validity in the U.S. Tom Engellenner AIPLA Presentation to.
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
Business Process/Methods & Software Patents IM 350: Intellectual Property Law and New Media Fall, 2015.
Josiah Hernandez What can be Patented. What can be patented A patent is granted to anyone who “invents or discovers any new and useful process, machine,
The Subject Matter of Patents II Class Notes: April 8, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
Prosecution Group Luncheon Patent October PTO News Backlog of applications continues to decrease –623,000 now, decreasing about 5,000/ month –Expected.
Software Patents for Higher Education by Bruce Wieder August 12, 2008 © 2008 Bruce Wieder.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
Introduction The Patentability of Human Genes Is patenting human genes moral? Should it be legal? Should there be international intervention?
Class 24: Finish Remedies, then Subject Matter Patent Law Spring 2007 Professor Petherbridge.
Chapter 18 The Federal Court System. Section 1, The National Judiciary Objectives: Objectives: 1. Explain why the Constitution created a national judiciary,
1 How To Find and Read the Law and Live to Tell (and Talk) About It Steve Baron January 29, 2009.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Jody Blanke, Professor Computer Information Systems and Law 1.
What did Enfish V Microsoft do? Dr. Sinai Yarus©
101 & Biotech Mercedes K. Meyer, Ph.D., J.D. Drinker Biddle & Reath LLP Is this part of a larger patent attack? 1.
IPO Section 101 Revisions (Patentable Subject Matter)
Bell Ringer – if you were not here last class, don’t ask me questions…. RQ #7 – STUDY!
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Commercial Litigation in the United States
Rapid Litigation Management v. Cellzdirect
The Challenge of Biotech Patent Eligibility in the United States:
Alexandria, Virginia July 21, 2014
The Federal Courts.
PATENTS IT.CAN Annual Meeting
United States - Software
Welcome to our Quiz Show
Biotechnology Chemical Pharmaceutical Customer Partnership
Chapter 18 “The Federal Court System”
ChIPs Global Summit, September 15, 2016
Monday, Aug. 26.
The Supreme Court and Constitutional Interpretation
Patent, Trademark & Trade Secret Law
The Mayo-Alice Dogma and Paths to Eligibility for BioPharma
Recent USPTO Developments on Subject Matter Eligibility
Comparing subject matter eligibility in us and eu
Courts and Court Systems
Subject Matter Eligibility
A tutorial and update on patentable subject matter
Florida Courts Scavenger Hunt
The Other 66 Percent: Appeals Before the PTAB
Presentation transcript:

Restoring the Patent System: Countering Supreme Court Attacks on What Can be Patented David Kappos Robert Armitage Bruce Sunstein Denise Kettelberger, moderator September 9, 2016

2

Topics How it started: Prometheus, Myriad, Alice Sequenom v. Ariosa: the Court is sticking to its guns Leaky life rafts from the Federal Circuit The environments for patent eligibility: PTO, federal trial courts, and their effect on infrastructure How should the problem be fixed? What to do in the meantime 3 3

Prometheus, Myriad, Alice Held: claimed subject matter is not patent- eligible: - (1) if it is deemed “directed to” a law of nature, a natural phenomenon, or an abstract idea, - (2) unless the claim taken as a whole defines an “inventive concept” that is “significantly more” than the law of nature, natural phenomenon, or abstract idea itself. Rationale: to prevent “improperly tying up the future use of’ these building blocks of human ingenuity” 4

The two-step test is not in the Patent Act Section 101 of the Patent Act makes patent- eligible “any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof” The Supreme Court says that its two-step test is based on an “implicit exception” to the Patent Act So some inventions that are eligible under section 101 are ineligible according to the Court 5 5

Sequenom v. Ariosa: Court is sticking to its guns Methods for detecting paternally-inherited fetal DNA in maternal blood samples, and performing a prenatal diagnosis based on such DNA, held patent-ineligible by the Federal Circuit Court of Appeal based on Prometheus In response to Sequenom’s petition for review to the Supreme Court, supported by 22 friend–of- court briefs, the Court issued a one-sentence summary denial of review 6 6

Leaky life rafts from the Federal Circuit DDR Holdings, Enfish, Bascom Global Internet Services, and CellzDirect found patent-eligible subject matter But in a sea of cases holding just the opposite: as of June 16, 2016, 95% of the Federal Circuit’s decisions affirmed patent-ineligibility determinations based on Prometheus, Myriad, and Alice with no dissents 7 7

The environments for patent eligibility In the Patent and Trademark Office In the federal district courts The effect of these environments on research and development, business, and the technological infrastructure in the United States 8 8

How should the problem caused by the Supreme Court be ultimately fixed? Legislation—More options than consensus - Abrogate—rely on remaining patentability requirements to address the Court’s policy concerns with patents relating to concepts and expressly overrule any § 101 “implicit exception.” - “Safe harbor”—leave the Mayo/Alice framework in place, but afford a statutory “safe harbor,” for claims meeting the safe-harbor requirements to be deemed outside the “implicit exception.” - Abrogate and Restate—abrogate any § 101 “implicit exception,” and restate select existing patentability requirements as new patent-eligibility limitations. - Codify a Substitute Framework—codify a substitute framework for administering the “implicit exception,” e.g., based upon a technological arts (useful arts) subject matter eligibility limitation. - Codify Enumerated Exceptions—develop an enumerated listing of subject matter to be statutorily ineligible for patenting, e.g., human genes, methods of doing business, human organisms, et cetera (list to be continued). 9 9 Desirability—Viability

How should the problem caused by the Supreme Court be ultimately fixed? Judicial—Can the “breaker” be the “fixer”? - Positioning the Supreme Court to again address its Mayo/Alice framework. - Building a consensus at the USPTO, Commerce, and the DOJ that this is an international issue where U.S. law is woefully out of step. - Identifying the single best “ask” of the Court—if not abrogation, then what alternative framework, e.g., the J. Stevens “technological” approach that would bar business method and other patents. - Creating the right vehicle—Sequenom was ideal, but garnered no traction— not even a Solicitor General referral—and another Sequenom may be hard to come by. - Preparing the law in the meantime—if we assume abrogation is the answer, the Federal Circuit must assure its interpretation of § 103/§ 112 take up any slack. - Garnering more published academic and empirical support that the status quo is an intolerable burden on innovation. 10

What to do in the meantime? Patent prosecution strategy: - build a factual record with declarations to tell the story of why the patent claims are not directed to a natural law or phenomenon or an abstract idea and, taken as a whole, are directed to “significantly more” than the exception - emphasize “technological” aspects of the invention - be mindful of clearly meeting the other patentability tests— e.g., disclosure/definiteness. Education of the public and Congress 11

Thank You